Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels


BrainsWay Ltd. (NASDAQ & TASE: BWAY) (BrainsWay or the Company), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that Christopher von Jako, Ph.D., President and Chief Executive Officer, will present and participate in one-on-one investor meetings at the Sidoti December Micro-Cap Investor Conference.


GlobeNewswire Inc | Nov 30, 2021 08:00AM EST

November 30, 2021

BURLINGTON, Mass. and JERUSALEM, Nov. 30, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (BrainsWay or the Company), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that Christopher von Jako, Ph.D., President and Chief Executive Officer, will present and participate in one-on-one investor meetings at the Sidoti December Micro-Cap Investor Conference.

Event: Sidoti December Virtual Micro-Cap Investor Conference Date: December 8-9, 2021Presentation: December 9, 2021, at 10 am ESTWebcast: https://sidoti.zoom.us/webinar/register/WN_VPWAO69rSE6J1Tp9kGmQVw

Management will also meet with investors during the event. Investors interested in meeting with the BrainsWay management team during the conference should contact their Sidoti representative.

About BrainsWayBrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with offices in Burlington, MA and Jerusalem, Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visitwww.brainsway.com.

ContactsScott Areglado SVP and Chief Financial Officer617-771-2287SAreglado@brainsway.com

Investors:Bob YedidLifeSci Advisors646-597-6989Bob@LifeSciAdvisors.com







Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC